Please assess the completion status of the following clinical trial:

Trial Title: GoldenCareTM for the Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Female aged 18 years or older~* Subject has clinical bacterial Vaginosis with 4 of 4 positive Amsel's criteria~* Negative pregnancy test~* For 7 day treatment period, subject agrees to refrain from using douches and intravaginal products (i.e. feminine deodorant sprays, spermicides, Nonoxynol-9 products, tampons, and condoms). Subject also agrees to refrain from taking oral or intravaginal antibiotics (unless enrolled in comparator arm),or antifungal agents during the entire study period.~Exclusion Criteria:~* Subject has another infectious or noninfectious cause of vulvovaginitis such asymptomatic candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex, human papilloma virus, atrophic vaginitis, lichen sclerosus, or genital warts.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metronidazole (Type: ACTIVE_COMPARATOR): Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
- GoldenCare (Type: EXPERIMENTAL): GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.

Based on this trial design, predict the completion outcome and termination type (if applicable).